EGFR and non-small cell lung carcinoma: Genetic tests are also used for therapeutic management, e.g. mutation testing in the epidermal growth factor receptor gene (EGFR) is used to predict the efficacy of the EGFR-targeting antibodies gefitinib and erlotinib, which are indicated for non-small cell lung cancer [3,4].